Search results
Added:
1 year ago
Long-term cardio-renal outcomes investigating empagliflozin (Boehringer Ingelheim) on kidney disease progression (KDP) or cardiovascular death in patients with pre-existing chronic kidney disease.In this short interview, Prof William Herrington (Nuffield Department of Population Health, University of Oxford, Oxford, UK) discusses the findings from EMPA-KIDNEY (NCT03594110).EMPA-KIDNEY is an…
View more
Obesity and CKD: The Dual Epidemic in Cardiovascular Health
Added:
5 months ago
Review Article
Added:
1 year ago
RP-UN-CAR-GB-0166 / June 2024This programme features a compelling discussion between two distinguished experts, Prof Pam Taub (University of California, San Diego, US) and Prof Nikolaus Marx (University Hospital RWTH, Aachen, DE), chairperson responsible for the most recent ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes. Together, they delve into a critical…
View more
Added:
2 years ago
ERA 23 - In this short video from ERA 23, we are joined by Dr Navdeep Tangri (Max Rady College of Medicine, Manitoba, CA) to discuss the findings from the REVEAL-CKD Trial.
REVEAL-CKD is a retrospective, multinational, non-interventional, observational study which aimed to investigate the prevalence and consequences of undiagnosed chronic kidney disease (CKD) in a cohort of 670000 participants.
…
View more
New Horizons in Cardio Kidney Disease
Start date:
Jun 30, 2026
Broadcast
Cardiac Troponins in Kidney Disease
Added:
8 months ago
Review Article
Added:
1 month ago
Source:
Radcliffe CVRM
The CONFIDENCE trial investigated the efficacy of dual Empagliflozin & Finerenone therapy in compound CKD-T2D patients compared to Finerenone monotherapy in hyperkalemia prevention. The results suggested that dual therapy did not significantly mitigate hyperkalemia risk compared to solitary Finerenone administration.¹MethodologyThe CONFIDENCE trial was a double-blind, randomised, controlled study…
View more
Added:
10 months ago
ERA 2025 - Real-world outcomes show switching from treatment with steroidal mineralocorticoid receptor antagonists (sMRAs) to finerenone is a safe option in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D).Dr Beatriz Fernandez Fernandez (Hospital Universitario Fundación Jiménez Dïaz, Madrid, ES) joins us to discuss real-world outcomes from a study investigating the effect of…
View more
Added:
1 year ago
AHA Conference 2024 — Semaglutide shows increased benefits in CKD patients based on their cardiovascular status and risk profile.Dr Harriette Van Spall (McMaster University, CA) sits down with Dr Katherine Tuttle (University of Washington, US) to discuss the effects of semaglutide in patients with chronic kidney disease (CKD).The FLOW trial (NCT03819153) is designed to assess the effect of…
View more
Added:
1 year ago
ESC Congress 2024 — Finerenone improved outcomes in two trials in patients with CKD with T2D, and in patients with HFmrEF and HFpEF.Investigator, Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, US) joins us in London to discuss the findings from the FINE-HEART pooled analysis (Bayer).FINE-HEART is a pre-specified, exploratory pooled analysis combining data from three phase III clinical…
View more